相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling
Jacqueline G. Gerhart et al.
CLINICAL PHARMACOKINETICS (2022)
Oral levofloxacin: population pharmacokinetics model and pharmacodynamics study in bone and joint infections
Etienne Canoui et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)
Application of a dual mechanistic approach to support bilastine dose selection for older adults
Chaejin Kim et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
Pseudomonas aeruginosa Susceptibility in Spain: Antimicrobial Activity and Resistance Suppression Evaluation by PK/PD Analysis
Ana Valero et al.
PHARMACEUTICS (2021)
Development and evaluation of physiologically based pharmacokinetic drug-disease models for predicting captopril pharmacokinetics in chronic diseases
Muhammad F. Rasool et al.
SCIENTIFIC REPORTS (2021)
Antibiotic pharmacokinetics/pharmacodynamics: where are we heading?
Jian Li et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling
Brian Cicali et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
Effects of the Fluoroquinolones Moxifloxacin and Levofloxacin on the QT Subintervals: Sex Differences in Ventricular Repolarization
Jorg Taubel et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Urogenital infections
Florian Wagenlehner
WORLD JOURNAL OF UROLOGY (2020)
Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility
Emilie M. Gieling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients
Alan Abdulla et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Influence of Renal Function and Age on the Pharmacokinetics of Levofloxacin in Patients with Bone and Joint Infections
Gauthier Eloy et al.
ANTIBIOTICS-BASEL (2020)
Pharmacokinetic/pharmacodynamic target attainment of ciprofloxacin in adult patients on general wards with adequate and impaired renal function
Suzanne L. de Vroom et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents
M. L. Rizk et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In the Line of Fire: Should Urologists Stop Prescribing Fluoroquinolones as Default?
Gernot Bonkat et al.
EUROPEAN UROLOGY (2019)
Defining optimal dosing of ciprofloxacin in patients with septic shock
Jason A. Roberts et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997-2016
Dee Shortridge et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
The Importance of Antimicrobial Resistance Monitoring Worldwide and the Origins of SENTRY Antimicrobial Surveillance Program
Andrew S. Fuhrmeister et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review
Chandra Datta Sumi et al.
CLINICAL PHARMACOKINETICS (2019)
Time to Adapt Our Practice? The European Commission Has Restricted the Use of Fluoroquinolones since March 2019
Gernot Bonkat et al.
EUROPEAN UROLOGY (2019)
Moxifloxacin in Chronic Obstructive Pulmonary Disease: Pharmacokinetics and Penetration into Bronchial Secretions in Ward and Intensive Care Unit Patients
Maria Sionidou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Development and Evaluation of Physiologically Based Pharmacokinetic Drug-Disease Models for Predicting Rifampicin Exposure in Tuberculosis and Cirrhosis Populations
Muhammad F. Rasool et al.
PHARMACEUTICS (2019)
Pharmacokinetic/pharmacodynamic analysis as a tool for surveillance of the activity of antimicrobials against Pseudomonas aeruginosa strains isolated in critically ill patients
Ana Valero et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2019)
Population pharmacokinetic modeling to establish the role of P-glycoprotein on ciprofloxacin distribution to lung and prostate following intravenous and intratracheal administration to Wistar rats
Estevan Sonego Zimmermann et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Ciprofloxacin in critically ill subjects: considering hepatic function, age and sex to choose the optimal dose
Xia Li et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017
Ian A. Critchley et al.
PLOS ONE (2019)
Revisiting Oral Fluoroquinolone and Multivalent Cation Drug-Drug Interactions: Are They Still Relevant?
Stuart K. Pitman et al.
ANTIBIOTICS-BASEL (2019)
Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective cohort study
A. J. Stewardson et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
Individualising Therapy to Minimize Bacterial Multidrug Resistance
A. J. Heffernan et al.
DRUGS (2018)
Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives
Femke de Velde et al.
PHARMACOLOGICAL RESEARCH (2018)
Indications for Systemic Fluoroquinolone Therapy in Europe and Prevalence of Primary-Care Prescribing in France, Germany and the UK: Descriptive Population-Based Study
Daniel R. Morales et al.
CLINICAL DRUG INVESTIGATION (2018)
Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients
Simone H. J. van den Elsen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Population Pharmacokinetics of Levofloxacin in Plasma and Bone of Patients Undergoing Hip or Knee Surgery
Ulrich Gergs et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2018)
Multidisciplinary approach to prostatitis
Vittorio Magri et al.
ARCHIVIO ITALIANO DI UROLOGIA E ANDROLOGIA (2018)
Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function
Pier Giorgio Cojutti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection
Muhammad W. Sadiq et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)
Food effect: The combined effect of media pH and viscosity on the gastrointestinal absorption of ciprofloxacin tablet
Asma Radwan et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia
Issei Tokimatsu et al.
INTERNAL MEDICINE (2017)
Meta-analysis of the efficacy of moxifloxacin in treating Mycoplasma genitalium infection
Yang Li et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2017)
PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside
Catharine C. Bulik et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)
High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli
Pinyo Rattanaumpawan et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2017)
Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection
Michael Trang et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Mounting resistance of uropathogens to antimicrobial agents: A retrospective study in patients with chronic bacterial prostatitis relapse
Konstantinos Stamatiou et al.
INVESTIGATIVE AND CLINICAL UROLOGY (2017)
Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years' Experience 1991-2015
Ziyad S. Almalki et al.
PHARMACOECONOMICS-OPEN (2017)
Does Critical Illness Change Levofloxacin Pharmacokinetics?
Jason A. Roberts et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration
Estevan Sonego Zimmermann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Identifying 24h variation in the pharmacokinetics of levofloxacin: a population pharmacokinetic approach
Laura Kervezee et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Pharmacokinetics and pharmacodynamics in antibiotic dose optimization
Sherwin K. B. Sy et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians
Tomoko Hasunuma et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing
Nikolas J. Onufrak et al.
CLINICAL THERAPEUTICS (2016)
Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients
Claire Roger et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Population pharmacokinetics of levofloxacin in Korean patients
Sungmin Kiem et al.
JOURNAL OF CHEMOTHERAPY (2016)
Fluoroquinolone-Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?
Monique R. Bidell et al.
PHARMACOTHERAPY (2016)
Trends in Antibiotic Resistance in Urologic Practice
Hala Kandil et al.
EUROPEAN UROLOGY FOCUS (2016)
Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents
Eduardo Asin-Prieto et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2015)
The emerging threat of multidrug-resistant Gram-negative bacteria in urology
Hosam M. Zowawi et al.
NATURE REVIEWS UROLOGY (2015)
Pharmacokinetics and the optimal regimen for levofloxacin in critically ill patients receiving continuous hemodiafiltration
Takeshi Wada et al.
JOURNAL OF INTENSIVE CARE (2015)
Levofloxacin Dosing Regimen in Severely Morbidly Obese Patients (BMI ≥40 kg/m2) Should Be Guided by Creatinine Clearance Estimates Based on Ideal Body Weight and Optimized by Therapeutic Drug Monitoring
Manjunath P. Pai et al.
CLINICAL PHARMACOKINETICS (2014)
A Comprehensive Review on the Pharmacokinetics of Antibiotics in Interstitial Fluid Spaces in Humans: Implications on Dosing and Clinical Pharmacokinetic Monitoring
Tony K. L. Kiang et al.
CLINICAL PHARMACOKINETICS (2014)
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011)
Helio S. Sader et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2014)
Population pharmacokinetic analysis of ciprofloxacin in the elderly patients with lower respiratory tract infections
Agnieszka Cios et al.
EXPERIMENTAL GERONTOLOGY (2014)
The ciprofloxacin target AUC:MIC ratio is not reached in hospitalized patients with the recommended dosing regimens
Michiel Haeseker et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System
M. E. A. de Kraker et al.
CLINICAL MICROBIOLOGY AND INFECTION (2013)
Importance of Relating Efficacy Measures to Unbound Drug Concentrations for Anti-Infective Agents
Daniel Gonzalez et al.
CLINICAL MICROBIOLOGY REVIEWS (2013)
Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization
G. Cao et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2013)
Dosing Regimen Matters: the Importance of Early Intervention and Rapid Attainment of the Pharmacokinetic/Pharmacodynamic Target
Marilyn N. Martinez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Reevaluation of Moxifloxacin Pharmacokinetics and Their Direct Effect on the QT Interval
Philippe Grosjean et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Pharmacokinetics of Intravenous Levofloxacin Administered at 750 Milligrams in Obese Adults
Aaron M. Cook et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Population Pharmacokinetics and Penetration into Prostatic, Seminal, and Vaginal Fluid for Ciprofloxacin, Levofloxacin, and Their Combination
Jurgen B. Bulitta et al.
CHEMOTHERAPY (2011)
Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients
Martin G. Kees et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ciprofloxacin Hydrochloride
M. E. Olivera et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia
F. Scaglione et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China
Jing Zhang et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2009)
Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia
Sujata M. Bhavnani et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2008)
Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia
Kenichi Nomura et al.
INTERNAL MEDICINE (2008)
Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment
Juergen Barth et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis
Charles A. Peloquin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore
Paul G. Ambrose et al.
CLINICAL INFECTIOUS DISEASES (2007)
Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis
David Czock et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
The role of unbound drug in pharmacokinetics/pharmacodynamics and in therapy
R Calvo et al.
CURRENT PHARMACEUTICAL DESIGN (2006)
Estimation of pharmacokinetic parameters based on the patient-adjusted population data
Reza Mehvar
AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION (2006)
Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia:: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae
AM Noreddin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
The role of antibiotics in chronic bacterial prostatitis
FME Wagenlehner et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update
JW Mouton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2005)
Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia
GL Drusano et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients
SG Guenter et al.
PHARMACOTHERAPY (2002)
Clinical role of protein binding of quinolones
E Bergogne-Berezin
CLINICAL PHARMACOKINETICS (2002)
Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients
RS Malone et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration
E Hansen et al.
INTENSIVE CARE MEDICINE (2001)
Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials
A Aminimanizani et al.
CLINICAL PHARMACOKINETICS (2001)
A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin
GL Drusano et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: A review of microbiologic and pharmacokinetic pharmacodynamic characteristics
CH Nightingale
PHARMACOTHERAPY (2000)
分享论文
